FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Oncologic Drugs Ovarian Toxicity Guidance

[ Price : $8.95]

FDA publishes a draft guidance with recommendations to oncologic drug sponsors about measuring ovarian toxicity in relevant clinic...

Court Tosses Attorneys Privacy Suit Against FDA

[ Price : $8.95]

The DC federal court agrees with FDA that a suit against the agency over identifying an attorney in a regulated company on a form ...

Satsuma Pharma NDA Resubmission for Migraine Drug

[ Price : $8.95]

FDA accepts for review a Satsuma Pharmaceuticals NDA resubmission for STS101 (dihydroergotamine nasal powder) for the acute treatm...

Axsome to File NDA on Narcolepsy Drug

[ Price : $8.95]

Based on just-reported Phase 3 trial data, Axsome Therapeutics says it will submit an NDA for on AXS-12 (reboxetine) and its use i...

Follow-up Testing for Ames-Positive Drugs: Guide

[ Price : $8.95]

FDA posts a draft guidance entitled Recommended Follow-Up Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To S...

6 Observations on Regeneron FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with six observations from an inspection at Limerick, Ireland-based Regeneron Ireland Designated Act...

Trump Selects Johns Hopkins Makary as FDA Head

[ Price : $8.95]

President-elect Donald Trump names Johns Hopkins surgeon and public policy researcher Marty Makary as his nomination to be the nex...

Device EtO Sterilization Transitional Enforcement Policy

[ Price : $8.95]

FDA issues a final guidance entitled Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class 3...

Zimmer Biomet Cementless Partial Knee OKd

[ Price : $8.95]

FDA approves a Zimmer Biomet PMA supplement for its Oxford Cementless Partial Knee.

Alnylam Files sNDA for Vutrisiran

[ Price : $8.95]

FDA accepts for review an Alnylam Pharmaceuticals supplemental NDA for vutrisiran, an investigational RNAi therapeutic in developm...